18F-FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment
Accurate differential diagnosis of parkinsonism is of paramount therapeutic and prognostic
importance. In addition, with the development of invasive therapies and novel disease …
importance. In addition, with the development of invasive therapies and novel disease …
[HTML][HTML] Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease …
P Odin, KR Chaudhuri, JT Slevin, J Volkmann… - Parkinsonism & Related …, 2015 - Elsevier
Navigate PD was an educational program established to supplement existing guidelines
and provide recommendations on the management of Parkinson's disease (PD) refractory to …
and provide recommendations on the management of Parkinson's disease (PD) refractory to …
Breaking barriers: exploring mechanisms behind opening the blood–brain barrier
The blood–brain barrier (BBB) is a selectively permeable membrane that separates the
bloodstream from the brain. While useful for protecting neural tissue from harmful …
bloodstream from the brain. While useful for protecting neural tissue from harmful …
Levodopa–carbidopa intestinal gel in patients with Parkinson's disease: a systematic review
K Wirdefeldt, P Odin, D Nyholm - CNS drugs, 2016 - Springer
Background Levodopa–carbidopa intestinal gel (LCIG) is available in several countries for
the treatment of advanced levodopa-responsive Parkinson's disease (PD) with severe motor …
the treatment of advanced levodopa-responsive Parkinson's disease (PD) with severe motor …
Algorithms for the treatment of motor problems in Parkinson's disease
E Dietrichs, P Odin - Acta Neurologica Scandinavica, 2017 - Wiley Online Library
Several different strategies are effective for medical treatment of motor problems in
Parkinson's disease (PD). Many guidelines and evidence‐based reviews are available, but …
Parkinson's disease (PD). Many guidelines and evidence‐based reviews are available, but …
Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3 …
AJ Espay, F Stocchi, R Pahwa, A Albanese… - The Lancet …, 2024 - thelancet.com
Background Conventional oral levodopa therapy for the treatment of Parkinson's disease
can be associated with variations in plasma concentrations. Levodopa infusion strategies …
can be associated with variations in plasma concentrations. Levodopa infusion strategies …
Update on the management of Parkinson's disease for general neurologists
Management of Parkinson's disease (PD) is complicated due to its progressive nature, the
individual patient heterogeneity, and the wide range of signs, symptoms, and daily activities …
individual patient heterogeneity, and the wide range of signs, symptoms, and daily activities …
Interfacing electrogenic cells with 3D nanoelectrodes: position, shape, and size matter
An in-depth understanding of the interface between cells and nanostructures is one of the
key challenges for coupling electrically excitable cells and electronic devices. Recently …
key challenges for coupling electrically excitable cells and electronic devices. Recently …
Treatment of advanced Parkinson's disease
JC Giugni, MS Okun - Current opinion in neurology, 2014 - journals.lww.com
The optimization of levodopa is, in most cases, the most powerful therapeutic option
available; however, medication optimization requires an advanced understanding of …
available; however, medication optimization requires an advanced understanding of …
E ffect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced P arkinson's disease patients
Objective The purpose of this study was to assess the effect of levodopa‐carbidopa
intestinal gel (carbidopa‐levodopa enteral suspension) in advanced Parkinson's disease …
intestinal gel (carbidopa‐levodopa enteral suspension) in advanced Parkinson's disease …